Hospira Names Richard Davies Chief Commercial Officer
29 Janeiro 2012 - 1:03PM
PR Newswire (Canada)
LAKE FOREST, Ill., Jan. 30, 2012 /CNW/ - Hospira, Inc. , the
world's leading provider of injectable drugs and infusion
technologies, today announced that Richard Davies has been named
senior vice president and chief commercial officer. In this role,
he will be responsible for developing and executing Hospira's
global commercial strategies and delivering profitable revenue
growth across the company's product portfolio. Mr. Davies will join
Hospira Feb. 2 and serve as a member of Hospira's senior leadership
team, reporting to F. Michael Ball, chief executive officer.
(Photo: http://photos.prnewswire.com/prnh/20120130/CG43845) "From
catalyzing growth in well-established products to architecting bold
new strategies for emerging markets, Richard has a track record of
unparalleled success in the healthcare industry," said Mr. Ball.
"He is an accomplished and dynamic global commercial executive, and
we expect to leverage his deep expertise to advance our leadership
positions worldwide by executing customer-centric strategies and an
aggressive portfolio expansion initiative." Mr. Davies, 50, brings
to Hospira more than 20 years of diverse strategic and operational
experience gained through a variety of commercial management
positions and across a range of products and technologies. Most
recently, he served as vice president and general manager, Japan,
Asia Pacific and Latin America, for Amgen, where he was responsible
for establishing Amgen's business in the region as well as
supporting its strategy development for emerging markets overall.
During his eight years at Amgen, he led the company's commercial
organizations in Central/Eastern Europe and Australia, and also
served as vice president of U.S. sales for the immunology
franchise. Prior to joining Amgen, Mr. Davies spent 13 years at Eli
Lilly and Company in increasing roles of commercial responsibility,
including general country management. Born and educated in the
United Kingdom, Mr. Davies earned his bachelor's degree in applied
chemistry from the University of Portsmouth and his master of
business administration degree from the University of Warwick.
About HospiraHospira, Inc. is the world's leading provider of
injectable drugs and infusion technologies. Through its broad,
integrated portfolio, Hospira is uniquely positioned to Advance
Wellness™ by improving patient and caregiver safety while reducing
healthcare costs. The company is headquartered in Lake Forest,
Ill., and has approximately 14,000 employees. Learn more at
www.hospira.com. SOURCE Hospira, Inc. Hospira, Inc. CONTACT: Media,
Stacey Eisen, +1-224-212-2276, or Financial Community,KarenKing,
+1-224-212-2711, both of Hospira,
Inc.http://www.hospira.comhttp://photos.prnewswire.com/prnh/20040503/HSPLOGOhttp://photos.prnewswire.com/prnh/20120130/CG43845PRN
Photo Desk, photodesk@prnewswire.com
Copyright
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Hospira